EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy

Mitchell C Lock iD, Kimberley J Botting, Beth J Allison iD, Youguo Niu iD, Sage G Ford, Michael P Murphy, Sandra Orgeig, Dino A Giussani iD, Janna L Morrison iD

The Journal of Physiology · 2023-08 · 601 (16) · 3647-3665

DOI: 10.1113/jp284786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physiology, online erschienen am 19.07.2023. Verfasst von Mitchell C Lock und 8 weiteren Autor:innen. Beteiligte Einrichtung: Early Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Ad…. Hauptthemen laut MEDLINE: Antioxidants, Hypoxia, Organophosphorus Compounds. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic fetal hypoxaemia is a common pregnancy complication that increases the risk of infants experiencing respiratory complications at birth. In turn, chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in animal models of hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. However, whether antenatal antioxidant therapy confers any benefit on lung development in complicated pregnancies has not yet been investigated. Here, we tested the hypothesis that maternal antenatal treatment with MitoQ will protect the developing lung in hypoxic pregnancy in sheep, a species with similar fetal lung developmental milestones as humans. Maternal treatment with MitoQ during late gestation promoted fetal pulmonary surfactant maturation and an increase in the expression of lung mitochondrial complexes III and V independent of oxygenation. Maternal treatment with MitoQ in hypoxic pregnancy also increased the expression of genes regulating liquid reabsorption in the fetal lung. These data support the hypothesis tested and suggest that MitoQ as an antenatal targeted antioxidant treatment may improve lung maturation in the late gestation fetus. image Key points Chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. MitoQ is a targeted antioxidant that uses the cell and the mitochondrial membrane potential to accumulate within the mitochondria. Treatment of healthy or hypoxic pregnancy with MitoQ, increases the expression of key molecules involved in surfactant maturation, lung liquid reabsorption and in mitochondrial proteins driving ATP synthesis in the fetal sheep lung. There were no detrimental effects of MitoQ treatment alone on the molecular components measured in the present study, suggesting that maternal antioxidant treatment has no effect on other components of normal maturation of the surfactant system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntioxidantsHypoxiaOrganophosphorus CompoundsHumansInfant, NewbornPregnancyFemaleAnimalsSheepLungSurface-Active AgentsUbiquinone

Stichwörter der Autor:innen

antioxidantfetal growth restrictionfetushypoxialung developmentsurfactant

Substanzen

AntioxidantsmitoquinoneSurface-Active AgentsOrganophosphorus CompoundsUbiquinone

Autor:innen und Institutionen

  • Early Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.
  • Department of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.
  • MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
  • UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.

ORCID-Profile: Mitchell C Lock, Beth J Allison, Youguo Niu, Dino A Giussani, Janna L Morrison

Förderung

  • British Heart Foundation
  • Medical Research Council

Zitieren

APA

Lock, M. C., Botting, K. J., Allison, B. J., Niu, Y., Ford, S. G., Murphy, M. P., Orgeig, S., Giussani, D. A., & Morrison, J. L. (2023). MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy. The Journal of Physiology, 601(16), 3647-3665. https://doi.org/10.1113/jp284786

Vancouver

Lock MC, Botting KJ, Allison BJ, Niu Y, Ford SG, Murphy MP, et al. MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy. The Journal of Physiology. 2023;601(16):3647-3665. doi:10.1113/jp284786

BibTeX
@article{Lock2023,
  author = {Lock, Mitchell C and Botting, Kimberley J and Allison, Beth J and Niu, Youguo and Ford, Sage G and Murphy, Michael P and Orgeig, Sandra and Giussani, Dino A and Morrison, Janna L},
  title = {MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy},
  journal = {The Journal of Physiology},
  year = {2023},
  volume = {601},
  number = {16},
  pages = {3647--3665},
  doi = {10.1113/jp284786}
}
Kostenlos starten →